DERM Stock Overview
Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Journey Medical Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.40 |
| 52 Week High | US$8.11 |
| 52 Week Low | US$1.02 |
| Beta | 0.81 |
| 1 Month Change | 16.44% |
| 3 Month Change | -34.99% |
| 1 Year Change | 81.82% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -64.21% |
Recent News & Updates
Recent updates
Journey Medical Corporation (NASDAQ:DERM) Not Doing Enough For Some Investors As Its Shares Slump 31%
Mar 11
Journey Medical Corporation's (NASDAQ:DERM) 33% Dip In Price Shows Sentiment Is Matching Revenues
Jan 18Journey Medical Corporation's (NASDAQ:DERM) Price Is Right But Growth Is Lacking After Shares Rocket 26%
Nov 10US$12.00: That's What Analysts Think Journey Medical Corporation (NASDAQ:DERM) Is Worth After Its Latest Results
May 12Shareholder Returns
| DERM | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -11.9% | 0.08% | 1.2% |
| 1Y | 81.8% | 13.2% | 24.9% |
Return vs Industry: DERM exceeded the US Pharmaceuticals industry which returned 13.9% over the past year.
Return vs Market: DERM exceeded the US Market which returned 24.7% over the past year.
Price Volatility
| DERM volatility | |
|---|---|
| DERM Average Weekly Movement | 17.0% |
| Pharmaceuticals Industry Average Movement | 9.8% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: DERM's share price has been volatile over the past 3 months.
Volatility Over Time: DERM's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 41 | Claude Maraoui | journeymedicalcorp.com |
Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company’s marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also offers Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Exelderm cream and solution an antifungal intended for topical use; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; and Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis.
Journey Medical Corporation Fundamentals Summary
| DERM fundamental statistics | |
|---|---|
| Market cap | US$70.56m |
| Earnings (TTM) | -US$3.85m |
| Revenue (TTM) | US$79.18m |
0.9x
P/S Ratio-17.6x
P/E RatioIs DERM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DERM income statement (TTM) | |
|---|---|
| Revenue | US$79.18m |
| Cost of Revenue | US$26.66m |
| Gross Profit | US$52.52m |
| Other Expenses | US$56.37m |
| Earnings | -US$3.85m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.19 |
| Gross Margin | 66.33% |
| Net Profit Margin | -4.87% |
| Debt/Equity Ratio | 86.6% |
How did DERM perform over the long term?
See historical performance and comparison